Future strategies to prevent renal microvascular disease complications in diabetes

Future Cardiology

Volumn 4, Issue 1, 2008, Pages 77-83

  Karalliedde, Janaka ^a   Gnudi, Luigi ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

ACE inhibitors; Ang II receptor blockers; Blood pressure; Diabetes; Hypoglycemic agents; Kidney disease; Metabolism; Proteinuria; Renin angiotensin aldosterone system

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALAGEBRIUM; ALDOSTERONE; ALISKIREN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; PERINDOPRIL; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; SPIRONOLACTONE; SULODEXIDE; THIAZIDE DIURETIC AGENT; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; COMBINATION CHEMOTHERAPY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR;

EID: 38049181504     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.4.1.77     Document Type: Review

References (82)

1. Weening JJ: Advancing nephrology around the globe: an invitation to contribute. J. Am. Soc. Nephrol. 15, 2761-2762 (2004).
2. Jones CA, Krolewski AS, Rogus J et al.: Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int. 67, 1684-1691 (2005).
3. Chobanian AV, Bakris GL, Black HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
4. Cooper ME: Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44, 1957-1972 (2001).
5. Gnudi L, Thomas SM, Viberti G: Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J. Am. Soc. Nephrol. 18, 2226-2232 (2007).
6. Jamerson KA: Preventing chronic kidney disease in special populations. Am. J. Hypertens. 18, 106S-111S (2005).
7. Turnbull F, Neal B, Aigert C et al.: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med. 165, 1410-1419 (2005).
8. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br. Med. J. 317, 703-713 (1998).
9. Standards of medical care in diabetes - 2006. Diabetes Care 29(Suppl. 1), S4-S42 (2006).
10. Xue JL, Frazier ET, Herzog CA, Collins AJ: Association of heart disease with diabetes and hypertension in patients with ESRD. Am. J. Kidney Dis. 45, 316-323 (2005).
11. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K et al.: Albuminurta reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32, 219-226 (1989).
12. De Zeeuw D: Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int. 66(Suppl. 92), S2-S6 (2004).
13. Gerstein HC, Mann JF, Yi Q et al.: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286, 421-426 (2001).
14. Ruggenenti P, Schieppati A, Remuzzi G: Progression, remission, regression of chronic renal diseases. Lancet 357, 1601-1608 (2001).
15. Peterson JC, Adler S, Burkart JM et al.: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 123, 754-762 (1995).
16. Long DA, Price KL, Herrera-Acosta J et al.: How does angiotensin II cause renal injury? Hypertension 43, 722-723 (2004).
17. De Vriese AS, Stoenoiu MS, Eiger M et al.: Diabetes-induced microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide. Kidney Int. 60, 202-210 (2001).
18. Anderson S, Vora JP: Current concepts of renal hemodynamics in diabetes. J Diabetes Complications 9, 304-307 (1995).
19. Raij L: The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am. J. Hypertens. 18, 95S-99S (2005).
20. Maddox DA, Brenner BM: Glomerular ultrafiltration. In: The Kidney. 6th edition. Brenner BM, Rector FC Jr (Eds). WB Saunders Company, PA, USA 319-374 (2000).
21. Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: where hemodynamics meets metabolism. Exp. Clin. Endocrinol. Diabetes 115, 69-84 (2007).
22. Gnudi L, Viberti G, Raij L et al.: GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension 42, 19-24 (2003).
23. Inoki K, Haneda M, Maeda S et al.: TGFβ1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. kidney Int. 55, 1704-1712 (1999).
24. Weigert C, Brodbeck K, KlopferK et al.: Angiotensin II induces human TGF1β promoter activation: similarity to hyperglycaemia. Diabetologia 45, 890-898 (2002).
25. Ziyadeh FN: Mediators of diabetic renal disease: the case for TGFP as the major mediator. J. Am. Soc. Nephrol. 15(Suppl. 1), S55-S57 (2004).
26. Ziyadeh FN, Snipes ER, Watanabe M et al.: High glucose induces cell hypertrophy and stimulates collagen gene transcription in proximal tubule. Am. J. Physiol. 259, F704-F714 (1990).
27. Wolf G, Schroeder R, Ziyadeh FN et al.: High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: relationship to hypertrophy. Am. J. Physiol. 273, F348-F356 (1997).
28. Boffa JJ, Lu Y, Placier S et al.: Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases. J. Am. Soc. Nephrol. 14, 1132-1144 (2003).
29. Kato S, Luyckx VA, Ots M et al.: Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int. 56, 1037-1048 (1999).
30. Epstein M: Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am. J. Kidney Dis. 37, 677-688 (2001).
31. Iglarz M, Touyz RM, Viel EC et al.: Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction wtih the renin-angiaternion system. Am. J. Hypertem. 17, 597-603 (2004).
32. Ziyadeh FN, Hoffman BB, Han DC et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA 97, 8015-8020 (2000).
33. Chow FY, Nikolic-Paterson DJ, Ozols E et al.: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int. 69, 73-80 (2006)
34. Ferrara N, Gerber HP, Le Couter J: The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003)
35. De Vriese AS, Tilton RG, Eiger M et al.: Antibodies against vascular endothelial growth factor improve early renal dysfunction In experimental diabetes. J. Am. Soc. Nephrol. 12, 993-1000 (2001).
36. Sung SH, Ziyadeh FN, Wang A et al.: Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol. 17, 3093-3104 (2006).
37. Kuenen BC, Levi M, Meilers JC et al.: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler. Thromb. Vasc. Biol. 22, 1500-1505 (2002).
38. Yang JC, Haworth L, Sherry RM et al.: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
39. Eremina V, Cui S, Gerber H et al.: Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol. 17, 724-735 (2006).
40. Mathieson PW: How much VEGF do you need? J. Am. Soc. Nephrol. 17, 602-603 (2006).
41. Davis B, Dei Cas A, Long DA et al.: Podocyte-specific induced overexpression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J. Am. Soc. Nephrol. 18(8), 2320-2329 (2007).
42. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet 349, 1787-1792 (1997).
43. K/DOQ1 clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease: Am. J. Kidney Dis. 43, S1-S290 (2004).
44. Allen TJ, Cao Z, Youssef S et al.: Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 46, 1612-1618 (1997).
45. Yamagishi S, Fukami K, Ueda S et al.: Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr. Drug Targets 8, 952-959 (2007).
46. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia 39, 587-593 (1996).
47. Katayama S, Yagi S, Yamamoto H et al.: Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens. Res. 30, 529-533 (2007).
48. Rosario RF, Prabhakar S: Lipids and diabetic nephropathy. Curr. Diab. Rep. 6, 455-462 (2006).
49. Rossing P: Prediction, progression and prevention of diabetic nephropathy. The Minkowski lecture 2005. Diabetologia 49, 11-19 (2006).
50. Fioretto P, Steffes MW, Sutherland DE et al.: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339, 69-75 (1998).
51. Mogensen CE, Neldam S, Tikkanen I et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. Br. Med. J. 321, 1440-1444 (2000).
52. Mogensen CE, Viberti G, Halimi S et al.: Effect of low-close perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 41, 1063-1071 (2003)
53. Rossing P, Hommel E, Smidt UM et al.: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37, 511-516 (1994).
54. Schmieder RE, Klingbeil AU, Fleischmann EH et al.: Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J. Am. Soc. Nephrol. 16, 3038-3045 (2005).
55. Gaede P, Vedel P, Larsen N et al.: Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N. Eng. J. Med. 348, 383-393 (2003).
56. Rossing P, Hougaard P, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in Type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 25, 859-864 (2002).
57. Gaede P, Tarnow L, Vedel P et al.: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with Type 2 diabetes and microalbuminuria. Nephrol. Dial. Iramplant. 19, 2784-2788 (2004).
58. Schjoedt KJ, Rossing K, Juhl TR et al.: Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 70, 536-542 (2006).
59. O'Brien E, Barton J, Nussberger J et al.: Aliskiren reduces blood pressure and suppresses plasma renin activity In combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49, 276-284 (2007).
60. Kelly DJ, Zhang Y, Moe G et al.: Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy In rats. Diabetologia 50, 2398-2404 (2007).
61. Parving HH, Lewis EJ, Hollenberg NK: Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID). Presented at: Renal Week - American Society of Nephrology Meeting. San Francisco, CA, USA, October 31 - November 5 (2007).
62. Neuhofer W, Pittrow D: Role of endothelin and endothelin receptor antagonists in renal disease. Eur. J. Clin. Invest. 36(Suppl. 3), 78-88 (2006).
63. Sasser JM, Sullivan JC, Hobbs JL et al.: Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J. Am. Soc. Nephrol. 18, 143-154 (2007).
64. Tuttle KR, Bastyr EJ, McGill JB et al.: Albuminuria and kidney function in a longterm study of ruboxistaurin for diabetic neuropathy. Presented at: Renal Week-American Society of Nephrology Meeting. San Francisco, CA, USA, October 31 - November 5 (2007).
65. Gambaro G, van der Woude FJ: Glycosaminoglycans: use in treatment of diabetic nephropathy. J. Am. Soc. Nephrol. 11, 359-368 (2000).
66. Gambaro G, Kinalska I, Oksa A et al.: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric Type 1 and Type 2 diabetic patients: the Di.N.A.S. randomized trial. J. Am. Soc. Nephrol. 13, 1615-1625 (2002).
67. King GL, Brownlee M: The cellular and molecular mechanisms of diabetic complications. Endocrinol. Metab. Clin. North Am. 25, 255-270 (1996).
68. Gilbert RE, Kim SA, Tuttle KR et al.: Effect of ruboxistaurin on urinary transforming growth factor-β in patients with diabetic nephropathy and Type 2 diabetes. Diabetes Care 30, 995-996 (2007)
69. Kelly DJ, Zhang Y, Hepper C et al.: Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52, 512-518 (2003).
70. Thomas MC, Forbes JM, Cooper ME: Advanced glycation end products and diabetic nephropathy. Am. J. Ther. 12, 562-572 (2005).
71. Williams ME: Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr. Diab. Rep. 4, 441-446 (2004).
72. Coughlan MT, Thallas-Bonke V, Pete J et al.: Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 148, 886-895 (2007).
73. Cooper ME, Jandeleit-Dahm KA: Lipids and diabetic renal disease. Curr. Diab. Rep. 5, 445-448 (2005).
74. Fujii M, Inoguchi T, Maeda Y et al.: Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Kidney Int. 72, 473-480 (2007).
75. Tojo A, Asaba K, Onozato ML: Suppressing renal NADPH oxidase to treat diabetic nephropathy. Expert. Opin. Ther. Targets 11, 1011-1018 (2007).
76. Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. Ann. NY Acad. Sci. 1043, 440-451 (2005).
77. Miyazaki Y, Cersosimo E, Triplitt C et al.: Rosiglitazone decreases albuminuria in Type 2 diabetic patients. Kidney Int. 72 (11), 1367-1373 (2007).
78. Pistrosch F, Herbrig K, Kindel B et al.: Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54, 2206-2211 (2005).
79. Sarafidis PA, Bakris GL: Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 70, 1223-1233 (2006).
80. Dormandy JA, Charbonnet B, Eckland DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366, 1279-1289 (2005).
81. Home PD, Pocock SJ, Beck-Nielsen H et al.: Rosigiltazone evaluated for cardiovascular outcomes - an interim analysis. N. Engl. J. Med. 357, 28-38 (2007).
82. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).